{
    "risk_classification": "biotechnology",
    "confidence_score": 0.85,
    "social_media_risk": 0.15,
    "factors": [
        {
            "date": "2025-07-10",
            "title": "Klotho Neurosciences stock soars after FDA grants orphan drug status for ALS",
            "impact": "The FDA granting Orphan Drug Designation to Klotho's KLTO-202 for ALS treatment has significantly boosted investor confidence, leading to a 22% surge in stock price. This designation provides benefits such as tax credits, fee waivers, and market exclusivity, which are highly favorable for the company's future prospects."
        },
        {
            "date": "2025-06-30",
            "title": "Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS",
            "impact": "The announcement of moving forward with manufacturing and process development for KLTO-202 indicates progress towards clinical trials, which is a positive development for the company. This news likely contributed to positive investor sentiment and stock price movement."
        },
        {
            "date": "2025-06-24",
            "title": "Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa \"Blue Zone\", Announce a Plan to Study Tissue Levels of the Human Klotho Gene",
            "impact": "The partnership with the Okinawa Research Center for Longevity Science to study the Klotho gene's role in longevity and neurodegenerative diseases adds a promising dimension to Klotho's research portfolio. This collaboration may have positively influenced investor perception of the company's long-term potential."
        }
    ]
}